The estimated Net Worth of Kate Haviland is at least $3.29 Milion dollars as of 7 March 2024. Ms. Haviland owns over 12,464 units of Fulcrum Therapeutics Inc stock worth over $1,355,616 and over the last 9 years she sold FULC stock worth over $1,800,474. In addition, she makes $132,528 as Independent Director at Fulcrum Therapeutics Inc.
Kate has made over 29 trades of the Fulcrum Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 12,464 units of FULC stock worth $1,130,360 on 7 March 2024.
The largest trade she's ever made was exercising 21,644 units of Fulcrum Therapeutics Inc stock on 1 March 2019 worth over $500,626. On average, Kate trades about 3,929 units every 61 days since 2016. As of 7 March 2024 she still owns at least 153,177 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Ms. Haviland stock trades at the bottom of the page.
Kate Haviland serves as Independent Director of the Company. Ms. Haviland has served on our board of directors since June 2018. Ms. Haviland has served as chief operating officer of Blueprint Medicines Corporation, or Blueprint, a precision therapy company, since February 2019. Prior to her serving as chief operating officer, Ms. Haviland served as chief business officer of Blueprint from January 2016 to January 2019. Prior to that, from April 2014 to December 2015, Ms. Haviland served as vice president, rare diseases and oncology program leadership at Idera, a clinical-stage biopharmaceutical company, where she oversaw all aspects of the product development strategy for Idera’s rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution and commercial planning. Prior to joining Idera, from June 2012 to April 2014, Ms. Haviland served as head of commercial development at Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups. In addition, Ms. Haviland previously served as executive director of commercial development at PTC Therapeutics, Inc., a biopharmaceutical company, from March 2007 to June 2012 and held corporate development and project management roles at Genzyme, a biotechnology company, from July 2005 to April 2007. Ms. Haviland received a B.A. from Wesleyan University with a double major in biochemistry/molecular biology and economics and an M.B.A. from Harvard Business School.
As the Independent Director of Fulcrum Therapeutics Inc, the total compensation of Kate Haviland at Fulcrum Therapeutics Inc is $132,528. There are 7 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of $3,889,350.
Kate Haviland is 44, she's been the Independent Director of Fulcrum Therapeutics Inc since 2018. There are 12 older and 2 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
Kate's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk a Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include: